| Afr | Sear | Amr | Eur | Notes |
---|---|---|---|---|---|
Efficacy, assuming a 2-dose schedule at 2 & 3 months (1 dose only between brackets) | Â | Â | Â | Â | Â |
   Mild | 52% (52%) | 52% (52%) | 52% (52%) | 87% (87%) |  |
   Moderate | 55% (54%) | 55% (54%) | 55% (54%) | 92% (90%) |  |
   Severe | 60% (54%) | 60% (54%) | 60% (54%) | 100% (90%) |  |
Waning of efficacy (annual) | Â | Â | Â | Â | Â |
   Mild & moderate | 0.63 | 0.63 | 0.63 | 0.63 | multiply each next year |
   Severe | 0.83 | 0.83 | 0.83 | 0.83 | multiply each next year |
Coverage | Â | Â | Â | Â | Â |
   Dose 1 | 50% | 50% | 50% | 50% |  |
   Dose 2 | 40% | 40% | 40% | 40% |  |
   20 years after introduction | 80% | 80% | 80% | 96% | for both doses |
   Coverage improvement | linear | linear | linear | linear |  |
Per-dose vaccine costs (2 doses) | Â | Â | Â | Â | |
   2009-2014 | 7.5 | 7.5 | 7.5 | 45 |  |
   2015 & beyond | 4 | 4 | 4 | 45 |  |